RC108 / Rongchang Pharma - LARVOL DELTA

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: RemeGen Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial. (ASCO 2025) - P1/2 | "RC108+F showed encouraging antitumor activity with manageable safety profile in pts with MET-overexpression. At the same time, this study demonstrated better efficacy in the population with lower MET expression in the cytoplasm. We will continue to explore more beneficial populations in future studies."

Clinical • Combination therapy • Metastases • P1/2 data • Alopecia • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov) - P2 | N=240 | Active, not recruiting | Sponsor: RemeGen Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Oct 2024 ➔ Oct 2025

Enrollment closed • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MET

A Study of RC108-ADC in Subjects with Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: RemeGen Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor • MET

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov) - P1/2 | N=106 | Recruiting | Sponsor: RemeGen Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China (PRNewswire) - "Innovent Biologics...and RemeGen...announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT® (sintilimab injection) with RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate (ADC), or RC108, a novel c-Met-targeting ADC, respectively, as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent will provide clinical drug supplies of TYVYT® (sintilimab injection) during the clinical trial collaboration. RemeGen will conduct Phase 1/2a clinical studies to evaluate the anti-tumor activity and safety of the combination therapy of TYVYT® (sintilimab injection) with RC88 or RC108 in Chinese patients with advanced solid tumors."

Licensing / partnership • Oncology • Solid Tumor

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov) - P1/2 | N=106 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: RemeGen Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MET

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • MET

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: RemeGen; Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor • MET

RemeGen’s ADC RC108 nodded for study in c-Met+ solid tumors in China (GBI Health) - "China-based biopharma RemeGen Ltd (9995.HK) announced the go-ahead from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its antibody drug conjugant (ADC) RC108 in c-Met positive advanced solid tumors...RC108 is under development to treat advanced solid tumors as a monotherapy."

Non-US regulatory • Oncology • Solid Tumor